Skip to main content
Premium Trial:

Request an Annual Quote

Polyplus-transfection Licenses ZNA Oligonucleotides to Metabion

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Polyplus-transfection, a Strasbourg, France-based molecular and cell biology tools company, has inked a licensing deal covering zip nucleic acid (ZNA) oligonucleotides with German firm Metabion.

Under the terms of the agreement, Metabion has been granted a non-exclusive license to manufacture and commercialize Polyplus-transfection's ZNA oligonucleotides, a new technology that increases the affinity for nucleic acids without reducing specificity, the French firm said. Metabion, which is a custom nucleic acids supplier, has the right to sell the ZNA oligos for research and in vitro diagnostic applications, beginning March 22.

According to Polyplus-transfection, the ZNAs improve the performance of molecular hybridization techniques, such as PCR assays when used as primers or probes. The technology also increases the sensitivity of tests and the detection of mutations, the firm said.

Financial and other terms of the agreement were not disclosed.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.